drugset / Trial / NCT03061708

Trial of Single Agent AZD2014 in RICTOR Amplified GC Patients as Second-line Therapy

NCT03061708

Phase 2 Terminated 1 enrolled Samsung Medical Center
NaSingle-groupOpen-labelTreatment

Summary

Phase II trial of AZD2014 in RICTOR amplified or overexpressed GC patients as second-line chemotherapy AZD2014 50mg BD continuous schedule of a 28 day cycle

Timeline

Start
2017-02-01
Primary completion
2018-11-16
Completion
2018-11-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Vistusertib Small molecule 50 mg

Indications